AVANIR PHARMACEUTICALS, INC. 4
4 · AVANIR PHARMACEUTICALS, INC. · Filed Dec 22, 2014
Insider Transaction Report
Form 4
Siffert Joao MD
SVP, R&D
Transactions
- Exercise/Conversion
Common Stock
2014-12-18$2.59/sh+32,291$83,634→ 348,901 total - Tax Payment
Common Stock
2014-12-18$16.99/sh−19,204$326,276→ 329,697 total - Sale
Common Stock
2014-12-18$16.93/sh−15,505$262,500→ 314,192 total - Exercise/Conversion
Stock Option (right to buy)
2014-12-18−32,291→ 0 totalExercise: $2.59Exp: 2022-12-17→ Common Stock (32,291 underlying)
Footnotes (4)
- [F1]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- [F2]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
- [F3]Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F4]The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.